Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, School of Medicine, University of Pittsburgh, PA, USA; Pittsburgh Center for Pain Research, School of Medicine, University of Pittsburgh, PA, USA; Department of Neurobiology, School of Medicine, University of Pittsburgh, PA, USA.
Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.
Pancreatology. 2021 Dec;21(8):1411-1418. doi: 10.1016/j.pan.2021.09.016. Epub 2021 Sep 30.
Chronic pancreatitis (CP) is associated with debilitating refractory pain. Distinct subtypes of CP pain have been previously characterized based on severity (none, mild-moderate, severe) and temporal (none, intermittent, constant) nature of pain, but no mechanism-based tools are available to guide pain management. This exploratory study was designed to determine if potential pain biomarkers could be detected in patient serum and whether they associate with specific pain patterns.
Cytokines, chemokines, and peptides associated with nociception and pain were measured in legacy serum samples from CP patients (N = 99) enrolled in the North American Pancreatitis Studies. The unsupervised hierarchical cluster analysis was applied to cluster CP patients based on their biomarker profile. Classification and regression tree was used to assess whether these biomarkers can predict pain outcomes.
The hierarchical cluster analysis revealed a subset of patients with predominantly constant, mild-moderate pain exhibited elevated interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-2 (IL-2), tumor necrosis factor alpha (TNFα), and monocyte chemoattractant protein-1 (MCP1) whereas patients with higher interleukin-4 (IL-4), interleukin-8 (IL-8) and calcitonin gene related peptide (CGRP) were more likely to have severe pain. Interestingly, analyses of each individual biomarker revealed that patients with constant pain had reduced circulating TNFα and fractalkine. Patients with severe pain exhibited a significant reduction in TNFα as well as trends towards lower levels of IL-6 and substance P.
The observations from this study indicate that unique pain experiences within the chronic pancreatitis population can be associated with distinct biochemical signatures. These data indicate that further hypothesis-driven analyses combining biochemical measurements and detailed pain phenotyping could be used to develop precision approaches for pain management in patients with chronic pancreatitis.
慢性胰腺炎(CP)与使人虚弱的难治性疼痛有关。先前根据疼痛的严重程度(无、轻度-中度、重度)和时间(无、间歇性、持续性)特征对 CP 疼痛的不同亚型进行了描述,但目前尚无基于机制的工具可用于指导疼痛管理。本探索性研究旨在确定是否可以在患者血清中检测到潜在的疼痛生物标志物,以及它们是否与特定的疼痛模式相关。
在北美胰腺炎研究中纳入的 CP 患者(N=99)的遗留血清样本中测量了与伤害感受和疼痛相关的细胞因子、趋化因子和肽。应用无监督层次聚类分析根据患者的生物标志物谱对 CP 患者进行聚类。分类回归树用于评估这些生物标志物是否可以预测疼痛结果。
层次聚类分析显示,具有主要持续性、轻度-中度疼痛的患者亚群表现出较高的白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)、白细胞介素-2(IL-2)、肿瘤坏死因子-α(TNFα)和单核细胞趋化蛋白-1(MCP1),而具有较高白细胞介素-4(IL-4)、白细胞介素-8(IL-8)和降钙素基因相关肽(CGRP)的患者更有可能出现严重疼痛。有趣的是,对每个单独生物标志物的分析表明,持续性疼痛患者的循环 TNFα 和 fractalkine 减少。严重疼痛患者的 TNFα 显著降低,IL-6 和 P 物质水平也呈下降趋势。
本研究的观察结果表明,慢性胰腺炎人群中的独特疼痛体验可能与独特的生化特征相关。这些数据表明,进一步结合生化测量和详细疼痛表型的假设驱动分析可用于为慢性胰腺炎患者开发疼痛管理的精准方法。